164 related articles for article (PubMed ID: 31160295)
1. Excellent long-term survival of children with Down syndrome and standard-risk ALL: a report from the Children's Oncology Group.
Matloub Y; Rabin KR; Ji L; Devidas M; Hitzler J; Xu X; Bostrom BC; Stork LC; Winick N; Gastier-Foster JM; Heerema NA; Stonerock E; Carroll WL; Hunger SP; Gaynon PS
Blood Adv; 2019 Jun; 3(11):1647-1656. PubMed ID: 31160295
[TBL] [Abstract][Full Text] [Related]
2. Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group.
Matloub Y; Bostrom BC; Hunger SP; Stork LC; Angiolillo A; Sather H; La M; Gastier-Foster JM; Heerema NA; Sailer S; Buckley PJ; Thomson B; Cole C; Nachman JB; Reaman G; Winick N; Carroll WL; Devidas M; Gaynon PS
Blood; 2011 Jul; 118(2):243-51. PubMed ID: 21562038
[TBL] [Abstract][Full Text] [Related]
3. Retrospective analysis of late intensification therapy with high-dose methotrexate for standard-risk acute lymphoblastic leukemia in childhood (CCLSG-S811 study). The Children's Cancer and Leukemia Study Group.
Koizumi S; Fujimoto T; Sasaki K; Takeda T; Utsumi J; Mimaya J; Ohta S; Ninomiya T; Takaue Y
Int J Hematol; 1991 Aug; 54(4):307-13. PubMed ID: 1777605
[TBL] [Abstract][Full Text] [Related]
4. Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
Millot F; Suciu S; Philippe N; Benoit Y; Mazingue F; Uyttebroeck A; Lutz P; Mechinaud F; Robert A; Boutard P; Marguerite G; Ferster A; Plouvier E; Rialland X; Behard C; Plantaz D; Dresse MF; Philippet P; Norton L; Thyss A; Dastugue N; Waterkeyn C; Vilmer E; Otten J;
J Clin Oncol; 2001 Apr; 19(7):1935-42. PubMed ID: 11283125
[TBL] [Abstract][Full Text] [Related]
5. Randomized trial to compare LSA2L2-type maintenance therapy to daily 6-mercaptopurine and weekly methotrexate with vincristine and dexamethasone pulse for children with acute lymphoblastic leukemia.
Nagatoshi Y; Matsuzaki A; Suminoe A; Inada H; Ueda K; Kawakami K; Yanai F; Nakayama H; Moritake H; Itonaga N; Hotta N; Fujita K; Hidaka Y; Yamanaka T; Kawano Y; Okamura J
Pediatr Blood Cancer; 2010 Aug; 55(2):239-47. PubMed ID: 20582970
[TBL] [Abstract][Full Text] [Related]
6. Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children's Oncology Group CCG-1952 clinical trial.
Stork LC; Matloub Y; Broxson E; La M; Yanofsky R; Sather H; Hutchinson R; Heerema NA; Sorrell AD; Masterson M; Bleyer A; Gaynon PS
Blood; 2010 Apr; 115(14):2740-8. PubMed ID: 20124218
[TBL] [Abstract][Full Text] [Related]
7. Repetitive low dose oral methotrexate and intravenous mercaptopurine treatment for patients with lower risk B-lineage acute lymphoblastic leukemia. A Pediatric Oncology Group pilot study.
Mahoney DH; Camitta BM; Leventhal BG; Shuster JJ; Civin CJ; Ganick DJ; Lauer SJ; Steuber CP; Kamen BA
Cancer; 1995 May; 75(10):2623-31. PubMed ID: 7736409
[TBL] [Abstract][Full Text] [Related]
8. Methotrexate-associated toxicity in children with Down syndrome and acute lymphoblastic leukemia during consolidation therapy with high dose methotrexate according to ALL-BFM treatment regimen.
Kroll M; Kaupat-Bleckmann K; Mörickel A; Altenl J; Schewel DM; Stanullal M; Zimmermann M; Schrappe M; Cario G
Haematologica; 2020 Apr; 105(4):1013-1020. PubMed ID: 31371414
[TBL] [Abstract][Full Text] [Related]
9. Favorable survival maintained in children who have myeloid leukemia associated with Down syndrome using reduced-dose chemotherapy on Children's Oncology Group trial A2971: a report from the Children's Oncology Group.
Sorrell AD; Alonzo TA; Hilden JM; Gerbing RB; Loew TW; Hathaway L; Barnard D; Taub JW; Ravindranath Y; Smith FO; Arceci RJ; Woods WG; Gamis AS
Cancer; 2012 Oct; 118(19):4806-14. PubMed ID: 22392565
[TBL] [Abstract][Full Text] [Related]
10. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group.
Bostrom BC; Sensel MR; Sather HN; Gaynon PS; La MK; Johnston K; Erdmann GR; Gold S; Heerema NA; Hutchinson RJ; Provisor AJ; Trigg ME;
Blood; 2003 May; 101(10):3809-17. PubMed ID: 12531809
[TBL] [Abstract][Full Text] [Related]
11. Randomized comparison of moderate-dose methotrexate infusions to oral methotrexate in children with intermediate risk acute lymphoblastic leukemia: a Childrens Cancer Group study.
Lange BJ; Blatt J; Sather HN; Meadows AT
Med Pediatr Oncol; 1996 Jul; 27(1):15-20. PubMed ID: 8614385
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of minimal residual disease in high risk B-ALL: a report from Children's Oncology Group study AALL0232.
Borowitz MJ; Wood BL; Devidas M; Loh ML; Raetz EA; Salzer WL; Nachman JB; Carroll AJ; Heerema NA; Gastier-Foster JM; Willman CL; Dai Y; Winick NJ; Hunger SP; Carroll WL; Larsen E
Blood; 2015 Aug; 126(8):964-71. PubMed ID: 26124497
[TBL] [Abstract][Full Text] [Related]
13. [SLCO1B1c. 521T>C gene polymorphisms are associated with high-dose methotrexate pharmacokinetics and clinical outcome of pediatric acute lymphoblastic leukemia].
Zhang H; He X; Li J; Wang Y; Wang C; Chen Y; Niu C; Gao P
Zhonghua Er Ke Za Zhi; 2014 Oct; 52(10):770-6. PubMed ID: 25537545
[TBL] [Abstract][Full Text] [Related]
14. Intermediate-dose intravenous methotrexate and mercaptopurine therapy for non-T, non-B acute lymphocytic leukemia of childhood: a Pediatric Oncology Group study.
Camitta B; Leventhal B; Lauer S; Shuster JJ; Adair S; Casper J; Civin C; Graham M; Mahoney D; Munoz L
J Clin Oncol; 1989 Oct; 7(10):1539-44. PubMed ID: 2778483
[TBL] [Abstract][Full Text] [Related]
15. Outcome of acute lymphoblastic leukemia in children with down syndrome-Polish pediatric leukemia and lymphoma study group report.
Zawitkowska J; Odój T; Drabko K; Zaucha-Prażmo A; Rudnicka J; Romiszewski M; Matysiak M; Kwiecińska K; Ćwiklińska M; Balwierz W; Owoc-Lempach J; Derwich K; Wachowiak J; Niedźwiecki M; Adamkiewicz-Drożyńska E; Trelińska J; Młynarski W; Kołtan A; Wysocki M; Tomaszewska R; Szczepański T; Płonowski M; Krawczuk-Rybak M; Ociepa T; Urasiński T; Mizia-Malarz A; Sobol-Milejska G; Karolczyk G; Kowalczyk J
Pediatr Hematol Oncol; 2017 May; 34(4):199-205. PubMed ID: 29040012
[TBL] [Abstract][Full Text] [Related]
16. Comparison of intermittent or continuous methotrexate plus 6-mercaptopurine in regimens for standard-risk acute lymphoblastic leukemia in childhood (JCCLSG-S811). The Japanese Children's Cancer and Leukemia Study Group.
Koizumi S; Fujimoto T; Takeda T; Yatabe M; Utsumi J; Mimaya J; Ninomiya T; Yanai M
Cancer; 1988 Apr; 61(7):1292-300. PubMed ID: 3278798
[TBL] [Abstract][Full Text] [Related]
17. Neurodevelopmental outcome of infants with acute lymphoblastic leukemia: a Children's Cancer Group report.
Kaleita TA; Reaman GH; MacLean WE; Sather HN; Whitt JK
Cancer; 1999 Apr; 85(8):1859-65. PubMed ID: 10223582
[TBL] [Abstract][Full Text] [Related]
18. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy--a Pediatric Oncology Group study.
Mahoney DH; Shuster JJ; Nitschke R; Lauer SJ; Steuber CP; Winick N; Camitta B
J Clin Oncol; 1998 May; 16(5):1712-22. PubMed ID: 9586883
[TBL] [Abstract][Full Text] [Related]
19. 6-mercaptopurine dosage and pharmacokinetics influence the degree of bone marrow toxicity following high-dose methotrexate in children with acute lymphoblastic leukemia.
Schmiegelow K; Bretton-Meyer U
Leukemia; 2001 Jan; 15(1):74-9. PubMed ID: 11243403
[TBL] [Abstract][Full Text] [Related]
20. High-dose cyclophosphamide-high-dose methotrexate with coordinated intrathecal therapy for advanced nonlymphoblastic lymphoma of childhood: results of a Pediatric Oncology Group study.
Sullivan MP; Brecher M; Ramirez I; Ragab A; Hvizdala E; Pullen J; Shuster J; Berard C; Crist W; Vietti T
Am J Pediatr Hematol Oncol; 1991; 13(3):288-95. PubMed ID: 1793154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
